Medicus Pharma Ltd (MDCX)

$1.56 -0.01 (-0.64%)
Market Cap 35.25M
Revenue (ttm) 0.00
Net Income (ttm) -11.16M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 216,200
Avg Vol 315,602
Day's Range N/A - N/A
Shares Out 22.03M
Stochastic %K 48%
Beta -1.12
Analysts Strong Sell
Price Target $19.67

Company Profile

Medicus Pharma Ltd., a biotech/life sciences company, focuses on developing clinical development programs of therapeutic assets in the United States. It is developing SKNJCT-003, which is in Phase 2 study for the treatment of basal cell carcinoma of the skin. Medicus Pharma Ltd. has a strategic collaboration with the Gorlin Syndrome Alliance to access to SKINJECT in Patients with Gorlin Syndrome. The company was formerly known as Interactive Capital Partners Corporation and changed its name to M...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 610 540 7515
Address:
300 Conshohocken State Road, Suite 200, Conshohocken, United States
bullrider19
bullrider19 Jan. 8 at 9:22 PM
$MDCX SELL SELL about to take a BIG DIPPPPPPPPP below 1.30 bad news soon
0 · Reply
2TrustHim
2TrustHim Jan. 6 at 2:24 AM
$MDCX $2.59
0 · Reply
thebusthebus
thebusthebus Jan. 5 at 1:49 PM
$MDCX $HOOD $NVTS
0 · Reply
QuantumSwings
QuantumSwings Dec. 30 at 6:36 PM
$MDCX Expecting a big bottom bounce squeeze soon.
0 · Reply
BillionerOfKing
BillionerOfKing Dec. 30 at 6:34 PM
$MDCX Current Stock Price: $1.58
0 · Reply
2TrustHim
2TrustHim Dec. 30 at 12:43 PM
$MDCX $2.47 Coming With a Higher Run To Create The Dilution Needed To Drop Back To $1.57!!!Hope It Works out And Drug Trials Are A Success!!!
0 · Reply
JohnTrack
JohnTrack Dec. 30 at 11:04 AM
$MDCX seeing buzz https://www.rapidticker.com/news/mdcx-sec-filing-f0d6b9
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 30 at 4:47 AM
$MDCX
0 · Reply
2TrustHim
2TrustHim Dec. 29 at 8:42 PM
$MDCX AI Overview Current Status of SkinJect: Clinical Trials: SkinJect is currently being evaluated in a multi-center Phase 2 clinical study (SKNJCT-003) in the United States and Europe, and another study (SKNJCT-004) in the United Arab Emirates. Regulatory Pathway: The company has received positive feedback from the FDA regarding the 505(b)(2) regulatory pathway, which could streamline the approval process by leveraging existing safety data. Priority Review Application: Medicus Pharma has applied for a Commissioner's National Priority Voucher (CNPV), a program that aims to accelerate the timeline for products addressing national health priorities. This voucher, if obtained, could compress the new drug application timeline by approximately 8 to 10 months. No Approval Yet: As of late 2025, the company has completed patient enrollment for its current trials and hopes to announce top-line data in the first quarter of 2026, but no FDA approval has been issued.
0 · Reply
TrendNavigatorPrime
TrendNavigatorPrime Dec. 27 at 7:55 AM
$MDCX Expectations are resetting toward sustainable results, not one‑off wins. Resource allocation choices will signal strategic maturity. Predictability would attract a deeper institutional audience. Patience is warranted — but must be supported by results.
0 · Reply
Latest News on MDCX
Medicus Pharma Ltd. to Present at Biotech Showcase 2026 as SkinJect Phase 2 Clinical Data Approaches Readout and Partnering Readiness Accelerates

Jan 5, 2026, 7:30 AM EST - 3 days ago

Medicus Pharma Ltd. to Present at Biotech Showcase 2026 as SkinJect Phase 2 Clinical Data Approaches Readout and Partnering Readiness Accelerates

Medicus Pharma Ltd. Announces Engagement With Reliant AI to Develop Artificial Intelligence (AI) Driven Clinical Data Analytics Platform

Dec 22, 2025, 7:30 AM EST - 17 days ago

Medicus Pharma Ltd. Announces Engagement With Reliant AI to Develop Artificial Intelligence (AI) Driven Clinical Data Analytics Platform

Medicus Pharma Ltd. Completes Enrolment of Ninety (90) Patients for Phase 2 Clinical Study (SKNJCT-003) to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin

Dec 15, 2025, 7:30 AM EST - 24 days ago

Medicus Pharma Ltd. Completes Enrolment of Ninety (90) Patients for Phase 2 Clinical Study (SKNJCT-003) to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin

Medicus Pharma Ltd. Enters Into $5.1 Million Warrant Inducement

Dec 5, 2025, 3:20 PM EST - 4 weeks ago

Medicus Pharma Ltd. Enters Into $5.1 Million Warrant Inducement

Medicus Pharma Ltd. Appoints Carolyn Bonner as Chief Financial Officer in Addition to Her Role as President

Dec 1, 2025, 8:00 AM EST - 5 weeks ago

Medicus Pharma Ltd. Appoints Carolyn Bonner as Chief Financial Officer in Addition to Her Role as President

Medicus Pharma Ltd. Explore Novel Treatment Innovations that may Revolutionize Treatments for Prostate and Skin Cancers

Nov 24, 2025, 8:00 AM EST - 6 weeks ago

Medicus Pharma Ltd. Explore Novel Treatment Innovations that may Revolutionize Treatments for Prostate and Skin Cancers

Medicus Pharma Ltd. Announces Filing of FDA Commissioner's National Priority Voucher Application (CNPV) for SKNJCT-003 to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin

Nov 17, 2025, 7:30 AM EST - 7 weeks ago

Medicus Pharma Ltd. Announces Filing of FDA Commissioner's National Priority Voucher Application (CNPV) for SKNJCT-003 to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin

Medicus Pharma Ltd. Provides Corporate Updates and Reports Third Quarter 2025 Financial Highlights

Nov 14, 2025, 5:00 PM EST - 7 weeks ago

Medicus Pharma Ltd. Provides Corporate Updates and Reports Third Quarter 2025 Financial Highlights

Medicus Pharma Ltd. Receives Full United Kingdom Regulatory and Ethical Approvals To Expand Phase 2 Clinical Study (SKNJCT-003) To Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin

Nov 13, 2025, 7:30 AM EST - 2 months ago

Medicus Pharma Ltd. Receives Full United Kingdom Regulatory and Ethical Approvals To Expand Phase 2 Clinical Study (SKNJCT-003) To Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin

Medicus Pharma Ltd. Announces Collaboration with the Gorlin Syndrome Alliance to Pursue Compassionate Use Pathway for Skinject(TM) in Patients with Gorlin Syndrome

Oct 29, 2025, 7:30 AM EDT - 2 months ago

Medicus Pharma Ltd. Announces Collaboration with the Gorlin Syndrome Alliance to Pursue Compassionate Use Pathway for Skinject(TM) in Patients with Gorlin Syndrome

Medicus Pharma Ltd. Announces Collaboration with the Gorlin Syndrome Alliance to Pursue Compassionate Use Pathway for SKINJECT™ in Patients with Gorlin Syndrome

Oct 29, 2025, 7:30 AM EDT - 2 months ago

Medicus Pharma Ltd. Announces Collaboration with the Gorlin Syndrome Alliance to Pursue Compassionate Use Pathway for SKINJECT™ in Patients with Gorlin Syndrome

Medicus Pharma Ltd. Announces First Patient Treated in United Arab Emirates (UAE) Sknjct-004 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin

Oct 22, 2025, 7:30 AM EDT - 2 months ago

Medicus Pharma Ltd. Announces First Patient Treated in United Arab Emirates (UAE) Sknjct-004 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin

The Vanderbilt Report: Medicus Pharma Ltd Built Three Separate Billion-Dollar Bets

Oct 14, 2025, 8:07 AM EDT - 3 months ago

The Vanderbilt Report: Medicus Pharma Ltd Built Three Separate Billion-Dollar Bets

Medicus Pharma Ltd. to Present at The Maxim Growth Summit 2025

Oct 13, 2025, 7:30 AM EDT - 3 months ago

Medicus Pharma Ltd. to Present at The Maxim Growth Summit 2025

Medicus Pharma Ltd. to Present at the Family Office Summit in Dubai, UAE

Oct 7, 2025, 7:30 AM EDT - 3 months ago

Medicus Pharma Ltd. to Present at the Family Office Summit in Dubai, UAE

Medicus Pharma Ltd. Receives Positive Feedback From the Food and Drug Adminstration (FDA) Type C Meeting Supporting the Development of Skinject

Sep 29, 2025, 7:30 AM EDT - 3 months ago

Medicus Pharma Ltd. Receives Positive Feedback From the Food and Drug Adminstration (FDA) Type C Meeting Supporting the Development of Skinject

Stonegate Capital Partners Initiates Coverage on Medicus Pharma Ltd. (MDCX)

Sep 24, 2025, 9:26 AM EDT - 3 months ago

Stonegate Capital Partners Initiates Coverage on Medicus Pharma Ltd. (MDCX)

Medicus Pharma Ltd. To Present at Brookline Capital Markets

Sep 24, 2025, 7:30 AM EDT - 3 months ago

Medicus Pharma Ltd. To Present at Brookline Capital Markets

Medicus Pharma Ltd. Announces $8.0 Million Non-Dilutive Debenture Financing

Sep 18, 2025, 7:30 AM EDT - 4 months ago

Medicus Pharma Ltd. Announces $8.0 Million Non-Dilutive Debenture Financing

Medicus Pharma Ltd. Provides Update on United Arab Emirates (UAE) SKNJCT-004 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)

Sep 8, 2025, 7:30 AM EDT - 4 months ago

Medicus Pharma Ltd. Provides Update on United Arab Emirates (UAE) SKNJCT-004 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)

Medicus Pharma Ltd. Completes Acquisition of Antev Limited

Sep 2, 2025, 7:30 AM EDT - 4 months ago

Medicus Pharma Ltd. Completes Acquisition of Antev Limited

Medicus Pharma Ltd. Provides Update on Doxorubicin Containing Novel Microneedle Array (D-MNA) Clinical Development Program for the Treatment of Basal Cell Carcinoma (BCC) of the Skin and Reports Second Quarter 2025 Financial Highlights

Aug 21, 2025, 7:30 AM EDT - 5 months ago

Medicus Pharma Ltd. Provides Update on Doxorubicin Containing Novel Microneedle Array (D-MNA) Clinical Development Program for the Treatment of Basal Cell Carcinoma (BCC) of the Skin and Reports Second Quarter 2025 Financial Highlights

Medicus Pharma Ltd. Announces a Memorandum of Understanding (MOU) with Helix Nanotechnologies Inc. to Develop Thermostable Infectious Disease Vaccines

Aug 4, 2025, 7:30 AM EDT - 5 months ago

Medicus Pharma Ltd. Announces a Memorandum of Understanding (MOU) with Helix Nanotechnologies Inc. to Develop Thermostable Infectious Disease Vaccines

Medicus Pharma Ltd. Announces Voting Results Following the Annual and Special Meeting of Shareholders

Jul 23, 2025, 7:30 AM EDT - 6 months ago

Medicus Pharma Ltd. Announces Voting Results Following the Annual and Special Meeting of Shareholders

Medicus Pharma Ltd. to Present at BTIG Virtual Biotech Conference 2025

Jul 21, 2025, 7:30 AM EDT - 6 months ago

Medicus Pharma Ltd. to Present at BTIG Virtual Biotech Conference 2025

Medicus Pharma Ltd. Announces Submission of Type C Meeting Request to the Food and Drug Administration (FDA)

Jul 8, 2025, 7:30 AM EDT - 6 months ago

Medicus Pharma Ltd. Announces Submission of Type C Meeting Request to the Food and Drug Administration (FDA)

Medicus Pharma: High-Risk But Higher Reward For Their Potential Breakthrough Skin Cancer Treatment

Jul 4, 2025, 9:49 AM EDT - 6 months ago

Medicus Pharma: High-Risk But Higher Reward For Their Potential Breakthrough Skin Cancer Treatment

Medicus Pharma Ltd Announces a Definitive Agreement to Acquire Antev Ltd. UK

Jun 30, 2025, 7:30 AM EDT - 6 months ago

Medicus Pharma Ltd Announces a Definitive Agreement to Acquire Antev Ltd. UK

Medicus Pharma Ltd. Announces Appointment of Andrew Smith as Chief Operating Officer

Jun 23, 2025, 7:30 AM EDT - 7 months ago

Medicus Pharma Ltd. Announces Appointment of Andrew Smith as Chief Operating Officer

Medicus Pharma Ltd. to Present at 2025 Bio International Convention

Jun 12, 2025, 7:30 AM EDT - 7 months ago

Medicus Pharma Ltd. to Present at 2025 Bio International Convention

Medicus Pharma Ltd. Announces Submission of Product Development Plan to the Food and Drug Administration (FDA) to Treat External Squamous Cell Carcinoma (SCC) in Horses

Jun 9, 2025, 7:30 AM EDT - 7 months ago

Medicus Pharma Ltd. Announces Submission of Product Development Plan to the Food and Drug Administration (FDA) to Treat External Squamous Cell Carcinoma (SCC) in Horses

Medicus Pharma Ltd. Announces Closing of $7.0 Million Public Offering

Jun 2, 2025, 1:40 PM EDT - 7 months ago

Medicus Pharma Ltd. Announces Closing of $7.0 Million Public Offering

Medicus Pharma Ltd. Announces Pricing of $7.0 Million Public Offering

May 29, 2025, 8:30 PM EDT - 8 months ago

Medicus Pharma Ltd. Announces Pricing of $7.0 Million Public Offering

Medicus Pharma Ltd Receives Study May Proceed Approval from United Arab Emirates (UAE) Department of Health (DOH) to Commence Phase 2 Clinical Study (SKNJCT-004) to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)

May 22, 2025, 7:30 AM EDT - 8 months ago

Medicus Pharma Ltd Receives Study May Proceed Approval from United Arab Emirates (UAE) Department of Health (DOH) to Commence Phase 2 Clinical Study (SKNJCT-004) to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)

Medicus Pharma's 'Savvy' Antev Deal De-Risks Pipeline Expansion, Enhances Near-Commercial Portfolio

May 12, 2025, 2:20 PM EDT - 8 months ago

Medicus Pharma's 'Savvy' Antev Deal De-Risks Pipeline Expansion, Enhances Near-Commercial Portfolio

Medicus Pharma Ltd. Announces a Binding Letter of Intent to Acquire Antev Ltd.

Apr 28, 2025, 7:30 AM EDT - 9 months ago

Medicus Pharma Ltd. Announces a Binding Letter of Intent to Acquire Antev Ltd.

Medicus Pharma Provides Update on SKNJCT-003 Phase 2 Clinical Study for the Treatment of Nodular Basal Cell Carcinoma (BCC)

Apr 21, 2025, 7:30 AM EDT - 9 months ago

Medicus Pharma Provides Update on SKNJCT-003 Phase 2 Clinical Study for the Treatment of Nodular Basal Cell Carcinoma (BCC)

Medicus Pharma Ltd. Announces Closing of $4.2 Million Regulation A Offering

Mar 10, 2025, 4:05 PM EDT - 10 months ago

Medicus Pharma Ltd. Announces Closing of $4.2 Million Regulation A Offering

Medicus Pharma Ltd. Announces Pricing of $4.2 Million Regulation A Offering

Mar 6, 2025, 8:30 PM EST - 10 months ago

Medicus Pharma Ltd. Announces Pricing of $4.2 Million Regulation A Offering

Medicus Pharma Ltd Announces Positively Trending Interim Analysis for SKNJCT-003 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)

Mar 6, 2025, 7:30 AM EST - 11 months ago

Medicus Pharma Ltd Announces Positively Trending Interim Analysis for SKNJCT-003 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)

Medicus Pharma Ltd Announces Submission of Phase 2 Clinical Design (SKNJCT-004) to United Arab Emirates (UAE) Department of Health (DOH) to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)

Feb 27, 2025, 7:30 AM EST - 11 months ago

Medicus Pharma Ltd Announces Submission of Phase 2 Clinical Design (SKNJCT-004) to United Arab Emirates (UAE) Department of Health (DOH) to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)

Medicus Pharma Ltd. Enters into Standby Equity Purchase Agreement and Announces Intention to Voluntarily Delist from the TSX Venture Exchange (TSXV)

Feb 11, 2025, 7:41 AM EST - 11 months ago

Medicus Pharma Ltd. Enters into Standby Equity Purchase Agreement and Announces Intention to Voluntarily Delist from the TSX Venture Exchange (TSXV)

Medicus Pharma Ltd. Announces Minor Use (MUMS) Designation from the FDA for Doxorubicin-Containing Microneedle Array (D-MNA) Patch

Dec 12, 2024, 7:30 AM EST - 1 year ago

Medicus Pharma Ltd. Announces Minor Use (MUMS) Designation from the FDA for Doxorubicin-Containing Microneedle Array (D-MNA) Patch

Medicus Pharma Ltd. Announces Collaboration Agreement to Expand Phase 2 Clinical Study in Asia Pacific Region

Dec 2, 2024, 7:30 AM EST - 1 year ago

Medicus Pharma Ltd. Announces Collaboration Agreement to Expand Phase 2 Clinical Study in Asia Pacific Region

Medicus Pharma Ltd. Appoints Faisal Mehmud, MD, MRCP as Chief Medical Officer

Nov 18, 2024, 7:30 AM EST - 1 year ago

Medicus Pharma Ltd. Appoints Faisal Mehmud, MD, MRCP as Chief Medical Officer

Medicus Pharma Ltd. Announces Closing of US$4.0M Initial Public Offering in the United States

Nov 15, 2024, 4:47 PM EST - 1 year ago

Medicus Pharma Ltd. Announces Closing of US$4.0M Initial Public Offering in the United States

Medicus Pharma Ltd. Announces Pricing of US$4.0M Initial Public Offering in the United States

Nov 13, 2024, 6:45 PM EST - 1 year ago

Medicus Pharma Ltd. Announces Pricing of US$4.0M Initial Public Offering in the United States

bullrider19
bullrider19 Jan. 8 at 9:22 PM
$MDCX SELL SELL about to take a BIG DIPPPPPPPPP below 1.30 bad news soon
0 · Reply
2TrustHim
2TrustHim Jan. 6 at 2:24 AM
$MDCX $2.59
0 · Reply
thebusthebus
thebusthebus Jan. 5 at 1:49 PM
$MDCX $HOOD $NVTS
0 · Reply
QuantumSwings
QuantumSwings Dec. 30 at 6:36 PM
$MDCX Expecting a big bottom bounce squeeze soon.
0 · Reply
BillionerOfKing
BillionerOfKing Dec. 30 at 6:34 PM
$MDCX Current Stock Price: $1.58
0 · Reply
2TrustHim
2TrustHim Dec. 30 at 12:43 PM
$MDCX $2.47 Coming With a Higher Run To Create The Dilution Needed To Drop Back To $1.57!!!Hope It Works out And Drug Trials Are A Success!!!
0 · Reply
JohnTrack
JohnTrack Dec. 30 at 11:04 AM
$MDCX seeing buzz https://www.rapidticker.com/news/mdcx-sec-filing-f0d6b9
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 30 at 4:47 AM
$MDCX
0 · Reply
2TrustHim
2TrustHim Dec. 29 at 8:42 PM
$MDCX AI Overview Current Status of SkinJect: Clinical Trials: SkinJect is currently being evaluated in a multi-center Phase 2 clinical study (SKNJCT-003) in the United States and Europe, and another study (SKNJCT-004) in the United Arab Emirates. Regulatory Pathway: The company has received positive feedback from the FDA regarding the 505(b)(2) regulatory pathway, which could streamline the approval process by leveraging existing safety data. Priority Review Application: Medicus Pharma has applied for a Commissioner's National Priority Voucher (CNPV), a program that aims to accelerate the timeline for products addressing national health priorities. This voucher, if obtained, could compress the new drug application timeline by approximately 8 to 10 months. No Approval Yet: As of late 2025, the company has completed patient enrollment for its current trials and hopes to announce top-line data in the first quarter of 2026, but no FDA approval has been issued.
0 · Reply
TrendNavigatorPrime
TrendNavigatorPrime Dec. 27 at 7:55 AM
$MDCX Expectations are resetting toward sustainable results, not one‑off wins. Resource allocation choices will signal strategic maturity. Predictability would attract a deeper institutional audience. Patience is warranted — but must be supported by results.
0 · Reply
MoorMaster
MoorMaster Dec. 26 at 8:34 AM
$MDCX This name increasingly trades on execution rhythm rather than speculation about possibilities. Margins must remain resilient as activity scales. Capital misallocation remains the key downside risk. Proof, rather than potential, becomes the key differentiator.
0 · Reply
JohnTrack
JohnTrack Dec. 22 at 8:19 PM
$MDCX waiting for confirmation, yeah!!
1 · Reply
2TrustHim
2TrustHim Dec. 22 at 3:39 PM
$MDCX Always Something New Ready For Substantial Gains!!!
0 · Reply
JohnTrack
JohnTrack Dec. 22 at 2:18 PM
$MDCX Engagement With Reliant AI https://www.rapidticker.com/news/mdcx-medicus-pharma-ltd-announces-engagement-f3a013
0 · Reply
2TrustHim
2TrustHim Dec. 22 at 12:41 PM
$MDCX https://medicuspharma.com/medicus-pharma-ltd-announces-engagement-with-reliant-ai-to-develop-artificial-intelligence-ai-driven-clinical-data-analytics-platform/
0 · Reply
Brucemahler
Brucemahler Dec. 21 at 11:19 PM
$MDCX
0 · Reply
2TrustHim
2TrustHim Dec. 19 at 4:06 PM
$MDCX inspire The Workforce To Get To Buy The Options After They Triple In Value Would Be Nice!!!
0 · Reply
thebusthebus
thebusthebus Dec. 19 at 2:28 PM
$MDCX will double down at 1.50 if if drops to that.
0 · Reply
2TrustHim
2TrustHim Dec. 18 at 9:12 PM
$MDCX Nice options!!! Filing http://archive.fast-edgar.com/20251218/AS229222Z222L2Q822262M42QFOC6K22Z272
1 · Reply
2TrustHim
2TrustHim Dec. 17 at 4:27 PM
$MDCX https://youtu.be/S-OyeRrqqrE?si=yoRAdIvFFLA9rKWC
0 · Reply
DylanGFM
DylanGFM Dec. 17 at 2:15 AM
$MDCX https://medicuspharma.com/
0 · Reply
DylanGFM
DylanGFM Dec. 17 at 2:14 AM
$MDCX The company expects to release topline results for SKNJCT-003 in the first quarter of 2026 and secure an end of phase 2 (EOP2) meeting with the FDA in the first half of 2026. “Successfully completing the U.S. enrollment of 90 patients for SKNJCT-003 brings us one more step closer to bringing to market a non-invasive, patient friendly, cost effective, localized immune therapy to treat basal cell carcinoma of the skin which we believe represents ~$2 billion in potential market opportunity” stated Dr. Raza Bokhari, Medicus’s Executive Chairman & CEO. “We are very hopeful that the clinical study report expected in H1 2026 will reaffirm the positively trending preliminary interim data analysis that the Company released earlier this year in Q1 2025 which showed more than 60% clinical clearance in 26 patients.” SKNJCT-003 Clinical Trial Design
0 · Reply